New Releases from NCBI BookshelfPasireotide (Signifor LAR): Indication: For the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue: Reimbursement Recommendation [Internet].​Pasireotide (Signifor LAR): Indication: For the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Signifor LAR be reimbursed by public drug plans for the treatment of acromegaly if certain conditions are met.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top